BTSG · BrightSpring Health Services, Inc.

The thesis

BrightSpring Health Services is growing profit much faster than revenue, and the evidence modestly favours the shares. The first 2027 guidance, expected around late February 2027 with the fourth-quarter report, settles whether that pace clears management's 2027 goal of at least 15%-20% organic growth in adjusted EBITDA (earnings before interest, taxes, depreciation and amortization).

The 30 October 2026 third-quarter report was a clear beat and raise. Revenue rose 26.4% to $4.213 billion and adjusted EBITDA rose 42% to $227.8 million, per the company's 8-K release. Specialty pharmacy earns more per prescription, and the branches bought from Amedisys and LHC Group add home-health scale.

Valuation now carries more of the argument. Zacks put the shares at 30.9 times forward 12-month earnings on 5 November 2026, against 16.2 times for its sub-industry. Sales by KKR-affiliated holders and management remain the other main pressure on the price.

Bullish and bearish views on BrightSpring Health Services, Inc.

The bull case on BrightSpring Health Services, Inc. (BTSG), in brief: Revenue of $4.213 billion beat the $3.875 billion estimate in the same report. The bear case: The valuation already assumes success.

Bull case

• Revenue of $4.213 billion beat the $3.875 billion estimate in the same report.
• Full-year guidance raised again. On 30 October 2026 the company lifted 2026 revenue guidance to $15.900-$16.125 billion, from $15.100-$15.425 billion. Adjusted EBITDA guidance rose to $850-$860 million, from $820-$845 million per Zacks, which the 8-K puts at 37.6%-39.3% growth.
• A stated goal for 2027. Management reiterated at least 15%-20% organic adjusted EBITDA growth for 2027, Zacks reported on 5 November 2026. That gives the February report a clear yardstick.
• Specialty pharmacy drives the profit. Specialty and infusion revenue rose 33.8% to $3.18 billion in the third quarter, per Zacks. Gross profit per prescription rose 27% to $28.86, per TIKR on 30 October 2026, in what CFO Jennifer Phipps called in September the peak year of the Medicare drug-price hit. She expects the 2027 hit to be about half as large.
• Acquired branches lift home health. Provider Services revenue rose 31% to $481 million in the third quarter, with $79 million of segment EBITDA per the 8-K. Average daily home-health census reached 47,256, up 58%, helped by 107 acquired branches, per TIKR. The company expects those branches to add about $35 million of 2026 adjusted EBITDA.
• Debt falling quickly. Leverage was 1.79 times at 30 September 2026, down from 2.15 times at 30 June 2026. Third-quarter operating cash flow was $204.3 million, per the 8-K.
• Analysts raised targets. Guggenheim moved its target to $84 from $81 by 3 November 2026, per Investing.com, joining the 2 November 2026 increases from Leerink ($92), UBS ($92), TD Cowen ($84), Wells Fargo ($82) and Deutsche Bank ($73.50). Fiscal.ai put the median target at $84 on 3 November 2026.

Bear case

• The valuation already assumes success. Zacks reported on 5 November 2026 that the shares trade at 30.9 times forward earnings, against 16.2 times for the sub-industry and 21.8 times for the medical sector. It also reported a year-to-date gain of 86.4%, against 10% for the industry.
• Growth comes from price mix. Prescription volume rose only 1.5% in the third quarter while gross profit per script rose 27%, per TIKR on 30 October 2026. Most of the earnings growth depends on drug mix and pricing, which the company does not set.
• Medicare drug-price negotiation still bites. After the 31 July 2026 second-quarter report, management said the Inflation Reduction Act would cut 2026 home and community pharmacy revenue by about $200 million. The shares fell $13.12 to $59.76 in midday trading that day, per MarketBeat.
• Another price round takes effect in 2028. The third negotiation cycle covers 15 drugs and is the first to reach Medicare Part B, with final agreements due by 1 November 2026 and prices effective 1 January 2028, per Becker's and Mintz. Any overlap with BrightSpring's specialty mix would extend the headwind beyond the 2027 easing management describes.
• Steady supply from the main holders. KKR-affiliated holders and management sold 20 million shares at $41.15 in March 2026 and 15 million at $58.75 in June 2026, with no proceeds to the company. Both sales followed an earnings report. In June the company repurchased about 1.03 million of the offered shares, per a Reuters-based report.
• Exposure to reimbursement rules. The Centers for Medicare & Medicaid Services (CMS) proposed a 2.4% aggregate home-health payment increase for 2027 in July 2026. The final rule for 2026, issued 28 November 2025, cut payments by 1.3%, or $220 million.

Price setup

Adjusted daily closes show $65.86 on 5 November 2026. That is 9.7% below the 52-week high of $72.91 and 7.2% above the level of three months earlier. The 14-day relative strength index, a momentum gauge running from 0 to 100, stood at 61.2.

The shares rose 12% on the report, per TIKR, and 11.3% over the week to 5 November 2026, per Zacks. That recovers much of the 31 July 2026 decline without reaching the prior high. The June offering price of $58.75 sits below the $59.76 midday level reached on 31 July 2026, and it is the price where large holders last sold in size.

The narrative is maturing: the specialty pharmacy profit story is well known, and six brokers had raised targets by 3 November 2026, within two sessions of the report. Observable crowding sits in the valuation and the year-to-date gain. Underwritten holder sales are the other sign to track, and company news through 6 November 2026 shows no offering since June. No earnings date is close, since the next report is estimated for late February 2027.

Catalysts, next 30 days

• ~30 November 2026, est.: CMS final rule on 2027 home-health payments. The proposal put the aggregate increase at 2.4%. CMS issued last year's final rule on 28 November 2025.
• ~30 November 2026, est.: CMS publishes third-cycle negotiated drug prices. Mintz's summary of the draft timeline lists this date for prices effective 1 January 2028. The list shows how much of the specialty drug-price pressure carries into 2028.
• ~26 February 2027, est.: fourth-quarter report and first 2027 guidance. This falls outside the 30-day window, but the case turns on it. It tests the 15%-20% organic growth goal and the expected halving of the Medicare drug-price hit.

What would change the view

The case breaks if first 2027 adjusted EBITDA guidance falls below management's goal of at least 15%-20% organic growth, or if gross profit per script turns flat or down year over year at the fourth-quarter report. A statement that the 2027 Medicare drug-price hit will exceed about half the 2026 level would also undercut it.

On price, a daily close below $58.75 would put the shares under the June 2026 secondary-offering price. A new underwritten secondary offering followed by closes under $60 would show that holder supply is outweighing the earnings gains. A CMS final home-health update materially below 2.4% would weaken the Provider Services part of the case.

What it trades with

BrightSpring belongs with managed-care and health-services names such as Teladoc (TDOC), Ardent Health (ARDT), Surgery Partners (SGRY) and McKesson (MCK). The wider group's story has been maturing since late October after a saturated stretch through September, which raises the bar for any single name in it.

The shares look more tied to company results, CMS drug-price rules and KKR-related supply than to the group. TIKR's 30 October 2026 peer comparison supports that: Option Care Health's latest reported quarterly revenue rose 1.9% and CVS Health Services' rose 11.5%, against BrightSpring's 26.4%. That view would be wrong if the shares fell in step with these peers on days with no BrightSpring or CMS news.